Clinical Trial

A Study of LY3971297 in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
Protocol Amendment History 3 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-17
notable Primary completion moved earlier: 2026-09 -> 2026-08 2026-06-17
minor Completion moved earlier: 2026-09 -> 2026-08 2026-06-17
Trial Details
NCT Number NCT06148272
Lead Sponsor Eli Lilly and Company
Conditions Healthy, Obesity, Hypertension
Enrollment 225 participants
Start Date 2023-12-07
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16